drugset / Trial / NCT00531271
ABI-008 Trial in Patients With Metastatic Breast Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
To determine the maximum tolerated dose (MTD) and dose limiting toxicities (DLTs) of ABI-008 giver every 3 weeks; to characterize the toxicities of ABI-008; and to determine the pharmacokinetic parameters for ABI-008 when given on an every-3-week schedule to patients with metastatic breast cancer.
Timeline
- Start
- 2007-11-01
- Primary completion
- 2008-12-01
- Completion
- 2008-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ABI-008 | Unknown | 60 mg/m2 | Intravenous |
| Subject | ABI-008 | Unknown | 200 mg/m2 | Intravenous |